Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin's Lymphomas
Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with limited or no therapeutic options. Publication highlights in vitro and in vivo results supporting LP-284’s development for mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin's lymphoma (NHL) with immediate patient needs. Lantern is anticipating filing the IND application with the FDA and initiating a first-in-human Phase 1 trial for LP-284 in NHL, including MCL, during the second half of 2023.
Source: marketscreener.com
